The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms
详细信息 查看全文
- 作者：Silmara Mendes Martins Moulin ; Frederico Jacob Eutrópio…
- 关键词：Monitoring ; Cancer ; Hospital pharmacy ; Pharmaceutical intervention
- 刊名：Supportive Care in Cancer
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：25
- 期：3
- 页码：951-955
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine;
- 出版者：Springer Berlin Heidelberg
- ISSN：1433-7339
- 卷排序：25
文摘
PurposeChronic myeloid leukemia (CML) is a clonal myeloproliferative disease, accounting for 15 to 20% of leukemias, with an incidence of one to two cases/100,000 inhabitants. In Brazil, the estimated incidence of leukemia is six cases/100,000 men and 4.28 cases/100,000 women. CML is characterized by the presence of the Philadelphia chromosome. At present, three types of tyrosine kinase inhibitors (TKI) are administered to treat CML patients in the Brazilian public national health system (NHS), called the Unified Health System (in Portuguese, “Sistema Único de Saúde”, SUS). Such treatments are only effective if patients adhere to strict dosage regimens; protocol improvements that increase patient adherence to treatment would have economic and health benefits for overburdened health care systems. Here, pharmacist-monitored treatment is assessed.